Proactive Investors - Run By Investors For Investors

Benitec Biopharma begins phase II clinical study for head and neck cancer treatment

Drug sales for head and neck cancer treatment projected to rise to $1.53 billion in 2024.
a doctor examining a patient
The study will enrol up to 30 patients across Australia and Russia

Benitec Biopharma Ltd (ASX:BLT) (NASDAQ:BNTC) has commenced a phase II clinical study in Australia with BB-401 as a treatment for patients with head and neck squamous cell carcinoma (HNSCC).

The company is developing innovative therapeutics based on a combination of gene therapy and a patented gene-silencing technology called ddRNAi.

READ: Benitec Biopharma’s shares ride higher after securing new U.S. patent

The phase II open-label study has been designed to explore the safety, tolerability and efficacy of BB401 following injections into the lesions of patients with recurrent or metastatic head and neck cancer.

The study will enrol up to 30 patients at 5-8 sites across Australia and Russia.

Objective is to control the progression of cancer

BB-401 is a recombinant DNA (deoxyribonucleic acid) construct that produces an antisense RNA (ribonucleic acid) with specificity against Epidermal Growth Factor Receptor (EGFR).

More than 90% of lesions from patients show significantly increased EGFR levels associated with head and neck cancer.

The goal of this study is to inhibit the expression of EGFR in the treated lesions and thus control the progression of the disease and increase patient survival.

Significant market potential

In 2016, circa 64,000 new cases of head and neck cancer were estimated to have been diagnosed in the U.S., resulting in more than 13,000 deaths.

Total drugs sales for this type of cancer in the seven major markets (U.S., France, Germany, Italy, Spain, UK and Japan) is expected to increase from $386 million in 2014 to $1.53 billion in 2024.

Benitec’s new study represents an important milestone in the progression of BB-401 as a treatment option for patients with advanced head and neck cancer who have failed all other treatment modalities.

View full BLT profile View Profile

Benitec Biopharma Timeline

Newswire
August 18 2015

Related Articles

pippette
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
eye
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use